Recombinant von Willebrand factor (rVWF)

BIOLOGICAL2 trials

Sponsors

Baxalta now part of Shire

Conditions

Von Willebrand Disease

Phase 3

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

CompletedNCT01410227

Baxalta now part of ShireVon Willebrand Disease

Start: 2011-11-01End: 2014-02-01Updated: 2021-05-19

Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery

CompletedNCT02283268

Baxalta now part of ShireVon Willebrand Disease

Start: 2015-04-01End: 2016-07-06Updated: 2021-05-19

Related Papers

Exposure–Response Relationship between VWF/FVIII Activity and Spontaneous Bleeding Events Following Recombinant VWF Prophylaxis in Severe VWD

TH Open2024-04-011 citations

Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3.

2023-06-133 citations

Exposure-Response Relationship between Von Willebrand Factor (VWF) Activity and Bleeding Events Following Prophylaxis with Recombinant VWF (rVWF, vonicog alfa) in Patients with Severe Von Willebrand Disease (VWD)

Blood2021-11-051 citations

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.

2018-12-2050 citations

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

Blood2015-08-04153 citations